Deciphera Pharmaceuticals, Inc.
DCPHDelisted Jun 11, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001654151
Deciphera Pharmaceuticals, Inc. was delisted on Jun 11, 2024; its insiders filed their last Form 4 on Jun 11, 2024; 177 institutions reported holding it in 13F filings for Q1 2024, worth $943.7M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 177
- Q1 2024, +13 vs. previous quarter
- 13F value
- $943.7M
- Reported value at the end of Q1 2024
- Superinvestors holding
- 0
- At the end of Q1 2024
Superinvestors holding DCPH, Q1 2024
No superinvestor reported holding DCPH at the end of Q1 2024.
Latest insider trades
Open-market purchases and sales by Deciphera Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2024 (view filing) | Feb 16 | 4 days | Kelly Thomas PatrickChief Financial Officer | SSale | −3.01K | $15.62 | −$47.0K | −3.6%80.3K after | |
| Feb 20, 2024 (view filing) | Feb 16 | 4 days | Martin Daniel C.Chief Commercial Officer | SSale | −2.27K | $15.62 | −$35.4K | −4.0%55.1K after | |
| Feb 20, 2024 (view filing) | Feb 16 | 4 days | Sherman Matthew LEVP & Chief Medical Officer | SSale | −2.62K | $15.62 | −$40.8K | −2.3%108.7K after | |
| Feb 20, 2024 (view filing) | Feb 16 | 4 days | Pitman JamaSVP, Chief Development Officer | SSale | −2.27K | $15.62 | −$35.4K | −3.2%68.0K after | |
| Jan 18, 2024 (view filing) | Jan 16 | 2 days | Sherman Matthew LEVP & Chief Medical Officer | SSale | −2.44K | $14.47 | −$35.2K | −2.5%94.1K after | |
| Jan 18, 2024 (view filing) | Jan 16 | 2 days | Pitman JamaSVP, Chief Development Officer | SSale | −1.62K | $14.47 | −$23.5K | −3.1%50.6K after | |
| Jan 18, 2024 (view filing) | Jan 16 | 2 days | Kelly Thomas PatrickChief Financial Officer | SSale | −2.44K | $14.47 | −$35.2K | −3.6%66.1K after | |
| Jan 18, 2024 (view filing) | Jan 16 | 2 days | Martin Daniel C.Chief Commercial Officer | SSale | −1.62K | $14.47 | −$23.5K | −3.3%47.7K after | |
| Dec 14, 2023 (view filing) | Dec 13 | 1 day | Hoerter Steven L.President and CEO | SSale | −30.7K | $15.37 | −$471.3K | −29.6%72.8K after | |
| Dec 14, 2023 (view filing) | Dec 13 | 1 day | Pitman JamaSee Remarks | SSale | −1.66K | $15.37 | −$25.5K | −3.1%52.2K after |
Top 10 13F holders, Q1 2024
The largest institutional positions in Deciphera Pharmaceuticals, Inc. at the end of Q1 2024; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 5,994,276 | $94.3M | 0.00% | +18,010+0.3% | Added |
| Armistice Capital, LLC | 5,900,000 | $92.8M | 2.47% | +700,000+13.5% | Added |
| Redmile Group, LLC | 5,296,643 | $83.3M | 3.06% | +495,103+10.3% | Added |
| Deerfield Management Company, L.P. (Series C) | 5,127,270 | $80.7M | 1.40% | −660,754−11.4% | Reduced |
| Vanguard Group Inc | 4,565,044 | $71.8M | 0.00% | +163,408+3.7% | Added |
| State Street Corp | 3,098,806 | $48.7M | 0.00% | +627,993+25.4% | Added |
| Goldman Sachs Group Inc | 1,962,841 | $30.9M | 0.01% | −344,634−14.9% | Reduced |
| Dimensional Fund Advisors LP | 1,606,132 | $25.3M | 0.01% | +44,478+2.8% | Added |
| Morgan Stanley | 1,539,826 | $24.2M | 0.00% | −776,607−33.5% | Reduced |
| Polar Capital Holdings Plc | 1,500,000 | $23.6M | 0.14% | −350,000−18.9% | Reduced |